Keppra
Product Images NDC 54868-4947

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Keppra (NDC 54868-4947). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (500 mg Tablet Bottle)

Keppra 500 mg tablet bottle label from Physicians Total Care, Inc. Contains 30 tablets of levetiracetam. Label includes dosage instructions, child-resistant warnings, storage information, lot number, expiration date, and a barcode. Prominent branding with PIC Physicians Total Care logo.*

FDA Label Image

Principal Display Panel (750 mg Tablet Bottle)

Keppra 750 mg tablet bottle label by Physicians Total Care, Inc. The label indicates the active ingredient levetiracetam, with a 60-tablet count. It includes dispensing cautions, storage instructions to keep at room temperature, and child-resistant packaging information.*

FDA Label Image

Chemical Structure (Keppra 01)

Chemical structure diagram of the active ingredient in Keppra, showing atoms and bonds including a pyrrolidone ring and side chains, representing levetiracetam.*

FDA Label Image

Figure (Keppra 02)

A bar graph showing the percentage of patients by treatment group. The x-axis categorizes three groups: Placebo (N=95), KEPPRA 1000 mg/day (N=97), and KEPPRA 3000 mg/day (N=101). The y-axis represents the percentage of patients, ranging from 0% to 45%. The percentages are approximately 7.4% for Placebo, 37.1% for KEPPRA 1000 mg/day, and 39.6% for KEPPRA 3000 mg/day.*

FDA Label Image

Figure (Keppra 03)

A bar chart comparing the percentage of patients experiencing a certain outcome with placebo versus Keppra 3000 mg/day. The chart shows approximately 14.4% for placebo and 39.4% for Keppra with sample sizes of 104 and 180 patients respectively.*

FDA Label Image

Figure (Keppra 04)

A vertical bar chart comparing the percentage of patients across three groups: Placebo, Keppra 1000 mg/day, and Keppra 2000 mg/day. The percentages increase from 6.3% for Placebo to 20.8% for Keppra 1000 mg/day, and 35.2% for Keppra 2000 mg/day. Sample sizes for each group are also displayed beneath the group labels.*

FDA Label Image

Figure (Keppra 05)

A vertical bar chart comparing the percentage of patients between two groups: Placebo (97 patients) and Keppra (101 patients). The Placebo group shows 19.6% of patients, and the Keppra group shows 44.6%, with a notable increase in the Keppra group. The y-axis is labeled as percentage of patients.*

FDA Label Image

Figure (Keppra 06)

A bar chart comparing the percentage of patients between a placebo group and a Keppra group. The placebo group, consisting of 51 patients, shows about 19.6%, while the Keppra group, with 58 patients, shows about 43.1%.*

FDA Label Image

Figure (Keppra 07)

A bar chart comparing the percentage of patients between a placebo group (45.2%) and a Keppra group (72.2%). The x-axis shows the two groups labeled 'Placebo (N=84)' and 'Keppra (N=79),' and the y-axis represents the percentage of patients ranging from 0% to 100%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.